PrairieView Partners LLC Has $80,000 Holdings in Pfizer Inc. (NYSE:PFE)

by · The Cerbat Gem

PrairieView Partners LLC lifted its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 47.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,159 shares of the biopharmaceutical company’s stock after buying an additional 1,018 shares during the quarter. PrairieView Partners LLC’s holdings in Pfizer were worth $80,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of PFE. Pacer Advisors Inc. grew its position in shares of Pfizer by 856.8% during the 1st quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company’s stock worth $508,164,000 after buying an additional 17,957,928 shares during the period. Starboard Value LP acquired a new stake in shares of Pfizer during the 4th quarter worth approximately $407,730,000. Assenagon Asset Management S.A. grew its position in shares of Pfizer by 307.5% during the 1st quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company’s stock worth $254,574,000 after buying an additional 7,581,030 shares during the period. APG Asset Management N.V. grew its position in shares of Pfizer by 1,106.0% during the 4th quarter. APG Asset Management N.V. now owns 5,619,213 shares of the biopharmaceutical company’s stock worth $143,967,000 after buying an additional 5,153,257 shares during the period. Finally, AQR Capital Management LLC grew its position in shares of Pfizer by 299.5% during the 4th quarter. AQR Capital Management LLC now owns 6,698,797 shares of the biopharmaceutical company’s stock worth $177,719,000 after buying an additional 5,021,915 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of PFE opened at $24.69 on Wednesday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43. The firm’s 50 day moving average price is $24.39 and its two-hundred day moving average price is $24.54. The firm has a market cap of $140.37 billion, a P/E ratio of 17.89, a PEG ratio of 0.85 and a beta of 0.52.

Pfizer (NYSE:PFE – Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same quarter in the previous year, the firm posted $0.60 earnings per share. The business’s revenue was up 10.3% on a year-over-year basis. On average, analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer’s payout ratio is currently 124.64%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on PFE shares. Berenberg Bank lowered their price target on shares of Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a research report on Thursday, May 29th. Morgan Stanley lifted their price target on shares of Pfizer from $31.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 30th. HSBC reduced their price objective on shares of Pfizer from $27.00 to $26.00 and set a “buy” rating on the stock in a research note on Monday, May 19th. BMO Capital Markets reduced their price objective on shares of Pfizer from $36.00 to $30.00 in a research note on Thursday, April 17th. Finally, Citigroup lifted their price objective on shares of Pfizer from $23.00 to $25.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Pfizer has an average rating of “Moderate Buy” and an average price target of $28.28.

Get Our Latest Stock Report on Pfizer

Pfizer Company Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Articles

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).